Study: NCT00613457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: 10 mg/sqm/day from for 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase
Description: native E-coli Asparaginase 5,000 IU/sqm x 8 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase
Description: native E-coli Asparaginase 5,000 IU/sqm x 8 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asparaginase
Description: native E-Coli Asparaginase 10,000 IU/sqm x 4 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asparaginase
Description: native E-Coli Asparaginase 10,000 IU/sqm x 4 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asparaginase
Description: native E-Coli Asparaginase 10,000 IU/sqm x 4 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 1,000 mg/sqm i.v. 2 doses in Induction phase 1000 mg/sqm i.v. 1 dose in Protocoll II 500 mg/sqm i.v. 1 dose in protocol III

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 1,000 mg/sqm i.v. 2 doses in Induction phase 1000 mg/sqm i.v. 1 dose in Protocoll II 500 mg/sqm i.v. 1 dose in protocol III

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 1,000 mg/sqm i.v. 2 doses in Induction phase 1000 mg/sqm i.v. 1 dose in Protocoll II 500 mg/sqm i.v. 1 dose in protocol III

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 1,000 mg/sqm i.v. 2 doses in Induction phase 1000 mg/sqm i.v. 1 dose in Protocoll II 500 mg/sqm i.v. 1 dose in protocol III

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: 75 mg/sqm i.v.or s.c. 4 doses/week for 4 weeks in Induction phase 75 mg/sqm i.v.or s.c. 4 doses/week for 2 weeks in Protocol II and III

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: 75 mg/sqm i.v.or s.c. 4 doses/week for 4 weeks in Induction phase 75 mg/sqm i.v.or s.c. 4 doses/week for 2 weeks in Protocol II and III

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: 75 mg/sqm i.v.or s.c. 4 doses/week for 4 weeks in Induction phase 75 mg/sqm i.v.or s.c. 4 doses/week for 2 weeks in Protocol II and III

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: 75 mg/sqm i.v.or s.c. 4 doses/week for 4 weeks in Induction phase 75 mg/sqm i.v.or s.c. 4 doses/week for 2 weeks in Protocol II and III

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: 75 mg/sqm i.v.or s.c. 4 doses/week for 4 weeks in Induction phase 75 mg/sqm i.v.or s.c. 4 doses/week for 2 weeks in Protocol II and III

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin
Description: 30 mg/sqm i.v. 4 doses in Induction phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin
Description: 30 mg/sqm i.v. 4 doses in Induction phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: 30 mg/sqm i.v. x 4 doses in Protocol II and III

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: 30 mg/sqm i.v. x 4 doses in Protocol II and III

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: 30 mg/sqm i.v. x 4 doses in Protocol II and III

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 100 mg/sqm i.v. for 3 doses in HR block 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 100 mg/sqm i.v. for 3 doses in HR block 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: 800 mg/sqm i.v.q12h x 5 in HR block 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: 800 mg/sqm i.v.q12h x 5 in HR block 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Description: 60 mg/sqm p.o. c 28 days in Induction phase 60 mg/sqm p.o. x 56 days in Protocol M 50 mg/sqm daily in Maintenance phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Description: 60 mg/sqm p.o. c 28 days in Induction phase 60 mg/sqm p.o. x 56 days in Protocol M 50 mg/sqm daily in Maintenance phase